logo
Blood clots claim lives of young athletes, families advocate for awareness

Blood clots claim lives of young athletes, families advocate for awareness

Yahoo26-02-2025

The Brief
Gov. Brian Kemp declared March as Blood Clot Awareness Month in Georgia.
It comes after two families who lost their sons to blood clots brought up the idea to educate others about clotting risk factors.
Their goal is to raise awareness about blood clots, especially in kids and athletes.
ATLANTA - Up to 100,000 people die each year from blood clots, according to the Centers for Disease Control and Prevention.
About 25% of those who experience initial symptoms will die suddenly.
What we know
Twenty-one-year-old Bryce Stanfield, a Harrison High graduate and defensive tackle at Furman University, died last February.
Seventeen-year-old Denmark High School football star Finley Krutchen died in October.
Both athletes died from massive pulmonary embolisms where a blood clot blocks arteries in the lungs. They both had the clotting disorder Factor V Leiden.
What they're saying
"Finley didn't show any of the signs and symptoms that you would typically think, but he had pneumonia, and they thought maybe asthma and he saw a couple of different doctors...was cleared by cardiology a week before he went into cardiac arrest," Finley's mom, Veronica Krutchen said.
"Bryce was a 21-year-old athletic football player. He was diagnosed with muscle strains and an upper respiratory infection, maybe a touch of asthma. No one suspected that his symptoms would be related to a blood clot," Bryce's mom, Teri Stanfield, explained.
Both of the athletes' parents plan to head to Washington D.C. in March to continue to push for blood clot awareness on a national level.
"It just helps us know that our boys' voices will be heard," Krutchen added.
SEE ALSO:
Mother champions awareness of pulmonary embolisms in young athletes
Forsyth County teen football star suffers embolism; to be honored at game
The Source
FOX 5's Kim Leoffler spoke to the family of Bryce Stanfield and Finley Krutchen, who both died from blood clots.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

How CDC cuts affect women with chronic diseases like sickle cell
How CDC cuts affect women with chronic diseases like sickle cell

Yahoo

time2 hours ago

  • Yahoo

How CDC cuts affect women with chronic diseases like sickle cell

WESTLAND, Mich. — For D'Asia Jackson, every day is a guessing game over whether excruciating pain will upend her life. The 28-year-old medical assistant was born with sickle cell disease, an inherited condition that causes red blood cells to be shaped like a crescent moon. The anomaly can cause blood clots, organ damage and excruciating pain, which can worsen during the menstrual cycle. 'Pain-wise, I always describe it as like being hit by a Mack truck,' Jackson said. 'When I know my period is coming, I know pain is probably right behind it.' Over the last 10 years, Jackson has worked with her doctors to try a variety of contraception options to get her symptoms under control, from the Depo-Provera shot, a hormone injection given every three months, to an IUD to different forms of birth control pills. According to Jackson, none of them helped. Some made her periods even worse. 'I might have a good four or five good days of not bleeding in a month,' she said. 'Over the years, it's like the period actually started getting heavier, and that's when it started affecting my sickle cell.' At times, she's ended up in the hospital needing iron infusions due to loss of blood. Doctors don't know how to manage her symptoms. Sickle cell has no cure and treatment options are variable. 'The lack of education on sickle cell is very frustrating,' she said. 'I go into hospital stays having to educate doctors and nurses.' Now, women like Jackson are worried that lack of knowledge, particularly about how contraception affects their conditions, could get worse. In April, a small team that compiled information into what some consider the country's 'contraception bible,' a set of guidelines used by physicians to assess which types of birth control are safe for their patients, was fired from the Centers for Disease Control and Prevention as part of mass layoffs from the agency. The eight-person team was responsible for evaluating research and recommending birth control methods for patients with various conditions, from sickle cell disease, kidney disease and lupus to those at risk for HIV. The guidelines, called the U.S. Medical Eligibility Criteria for Contraceptive Use, provided the latest research for doctors, including an app that recommended which contraceptive methods were safe. The app has been downloaded more than 440,000 times, according to the CDC. Now, the work of that team has been halted as part of the reduction of the Women's Health and Fertility Branch of the Division of Reproductive Health. 'These are the only federal guidelines that focus on the safety of contraception for women with certain medical conditions,' said Lee Warner, the former chief of the Women's Health and Fertility Branch. 'This work exists nowhere else, and these individuals specialize in this area. Without their presence, the work stops.' Warner retired from the agency in April just after learning his team was being eliminated. 'While most women are able to use most methods, we looked at 60 conditions and over 1,800 evidence-based recommendations across an array of contraceptive methods,' he said. 'For some women, it is very dangerous for them to become pregnant at a certain point. So having contraception available to them that they can choose can help protect them.' At least 90% of people in the United States with sickle cell disease are Black. The maternal mortality rate for Black sickle cell patients has been found to be 26 times higher than for non-Black people. 'The CDC's decision to cut the team responsible for contraceptive guidelines is especially troubling for the sickle cell community, where pregnancy can carry severe health risks,' said Teonna Woolford, who founded the nonprofit Sickle Cell Reproductive Health Education Directive to advocate for patients and expand knowledge about the often-misunderstood disease. 'Eliminating this resource will disproportionately impact a community already facing significant barriers to care, further deepening health disparities.' In response to a request for comment, an official for the Department of Health and Human Services did not explain why the team was cut. In May, Health Secretary Robert F. Kennedy Jr. defended the cuts in a hearing before the Senate Health, Education, Labor and Pensions Committee. 'Right now we have 42 divisions that do maternal health,' Kennedy testified. 'They're not cuts. They're consolidations. It's ridiculous to have 42 divisions that are all supposed to be doing the same thing.' Warner disagreed with Kennedy's testimony. 'Especially with this branch,' he said, 'the expertise is not redundant of that elsewhere in the federal government.' 'Once this expertise is gone, it is permanently gone from the agency. It is going to be very hard to resume and re-create,' he said. 'The HHS restructuring consolidates maternal and child health programs into the new Administration for a Healthy America (AHA) to improve efficiency and better address public health needs,' an HHS official said in a statement to NBC News. 'The reorganization aims to streamline operations, maximize resources, and support key priorities like maternal mental health and data collection. We remain committed to improving health outcomes for American families.' Representatives for HHS did not specify if work on the contraception guidelines would continue. The Trump administration did not respond to questions about why the team was cut or if its work would continue. The CDC's most recent update to the contraception guidelines was published in August. The updates included new recommendations for people with sickle cell disease, finding that combined hormonal contraception presents an 'unacceptable health risk' due to patients' risk of life-threatening blood clots. In previous versions of the guidelines, the CDC found the advantages of combined hormonal birth control, which contains estrogen and progestin, outweighed potential risks such as blood clots or stroke. The newest guidelines also increased the risk category for the Depo-Provera shot, while ranking methods like progestin-only pills and IUDs as generally safe. Jackson was unaware of the updated guidance until her interview with NBC News. She said she is using an IUD as well as combined hormonal contraception in the form of a pill to try to manage her bleeding. 'I didn't know that,' she said. 'I kind of just hope that my doctor knows a lot and kind of just steers me in the right direction.' Warner said the CDC team should be publicizing the updated guidance now to make physicians aware of the changes and adjust how they treat patients. 'We actually planned to do a road show of the guidelines in the late fall and throughout the spring in which we would disseminate the guidelines and go speak to provider groups,' he said. 'It's not happening.' The severe pain associated with her periods has driven Jackson to seek a hysterectomy for relief. 'I have been asking for a hysterectomy for years. I've seen five different OBs, and no one will do it,' she said. While the current guidelines are still accessible, the August update could be the last, leaving Jackson with little hope that she'll find a method of birth control that works for her. 'I am terrified of how health care is going to go with all of these cuts being made,' she said. This article was originally published on

Domino's Pizza, McDonald's rating surprise tied to persistent consumer issue
Domino's Pizza, McDonald's rating surprise tied to persistent consumer issue

Miami Herald

time13 hours ago

  • Miami Herald

Domino's Pizza, McDonald's rating surprise tied to persistent consumer issue

Even the Hamburglar didn't see this one coming. Excessive weight has been a persistent problem in America, where at least one in five adults in each U.S. state is living with obesity, according to the Centers for Disease Control and Prevention. Don't miss the move: Subscribe to TheStreet's free daily newsletter As obesity rates have risen, so have scientists' efforts to address this serious health issue, which can cause asthma, heart disease, stroke, type 2 diabetes and even some cancers. Early attempts to treat obesity came to the market as early as the 1930s. Amphetamines were the prevalent treatment in the 1940s and 1950s and demand continued into the 1990s. Glucagon-like peptide-1 agonists, which mimic the action of the naturally occurring hormone GLP-1, have been available for about two decades. GLP-1 medications, including Ozempic, Wegovy, Zepbound and Mounjaro, have been used for years to treat Type 2 diabetes, and studies have found that they are also effective at encouraging weight loss. Wegovy and Ozempic are manufactured by Novo Nordisk (NVO) , while Eli Lilly (LLY) makes Zepbound and Mounjaro. Image source:One investment firm says increased use of these medications could have serious implications for two of the biggest names in the fast-food industry: McDonald's (MCD) and Domino's Pizza (DPZ) . The market for anti-obesity drugs, particularly those using injectable versions of GLP 1-based drugs, is still new and continuously evolving, Goldman Sachs said in a May 22 report. More Restaurants Beloved Mexican restaurant closing iconic location after 63 yearsMajor restaurant chain quietly closes several locationsIconic restaurant closing its doors after 32 years The investment firm lowered its projections for such medication and now forecasts the global market to reach $95 billion by 2030. That's down from the previous estimate of $130 billion to reflect trends influencing how the drugs are priced, how long patients stay on them, and how patient populations are segmented. Goldman lowered its U.S. market projections to a peak of $70 billion, but the firm sees room for greater penetration in markets outside the U.S. Goldman forecasts a market peak of $50 billion outside the US, compared with $35 billion previously. A survey of more than 50 doctors in the US found that lower doses of anti-obesity medications are working well for a majority of patients and insurance coverage is the most important factor in the decision-making process, Goldman Sachs wrote. "But to be clear, even with this moderated forecast, we see a significant growth opportunity for both existing players as well as new entrants into this market," said Asad Haider, head of the health-care business unit within Goldman Sachs Research. Demand for GPL-1 drugs could dramatically hinder the food and restaurant industries, according to a study from Cornell's SC Johnson College of Business and the data firm Numerator. The report, entitled "The No Hunger Games," found that households with at least one user of GLP-1 drugs reduced its grocery spending by about 6% within six months of starting the drugs. The spending cut was as much as 9% for higher-income households. "We also find an 8.6% decline in spending at fast-food chains, coffee shops and limited-service restaurants," the study said. "Our findings highlight the potential for GLP-1 medications to significantly change food demand, a trend with increasingly important implications for the food industry as GLP-1 adoption continues to grow." The study warned that common side effects of GLP-1 medications, such as nausea, vomiting and gastrointestinal discomfort, have reportedly led to reduced adherence or discontinued use for some patients. Related: McDonald's analyst grills new stock price target on McCrispy reaction "Moreover, their long-term efficacy and safety remain areas of ongoing investigation," the report said. Redburn Atlantic analyst Chris Luyckx focused on the growing adoption of GLP-1 in recent research reports. Luyckx double-downgraded McDonald's to sell from buy with a price target of $260, down from $319. The analyst expects the GLP-1 weight-loss drugs to suppress consumer appetites and says they present an underappreciated longer-term threat for McDonald's. A 1% drag on sales today "could easily build to 10% or more over time," particularly for restaurant brands skewed toward lower-income consumers, the analyst tells investors in a research note. McDonald's stock was down about 1.3% at last check and is up 18.5% from a year ago. Redburn Atlantic also initiated coverage of Domino's Pizza with a sell rating and $340 price target. Domino's, the world's largest pizza chain, faces the heaviest pressure from adoption of GLP-1 weight loss drugs, with high exposure to dinner occasions and lower-income consumers, the firm said. Redburn Atlantic said the company's organic traffic remains weak, with carry-out far outpacing delivery. Challenged system-sales growth and elevated consensus expectations present downside risk for Domino's, the firm said. McDonald's closed regular trading on June 10 down 1.4% at $300.43. Domino's shares were off 2.7% at $455.49. Related: Fund-management veteran skips emotion in investment strategy The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.

Former, current CDC employees call on RFK Jr. to resign
Former, current CDC employees call on RFK Jr. to resign

Axios

time15 hours ago

  • Axios

Former, current CDC employees call on RFK Jr. to resign

Current and former employees of Centers for Disease Control and Prevention are calling on Health Secretary Robert F. Kennedy Jr. to resign, warning that job cuts and proposed funding reductions will hurt the agency's ability to protect the public from future health outbreaks. Why it matters: The Atlanta-based CDC has long been the unbiased hub Americans turn to for facts about health topics, including sexually transmitted infections, maternal and infant health and respiratory infections. Driving the news: Carrying a large American flag, dozens of current employees at the facility walked out in protest of the cuts and joined people rallying in support of the department. Tuesday's protest attracted more than 100 people who packed the sidewalk along Clifton Road across from the CDC's headquarters. What they're saying: Sarah Boim, a member of Fired But Fighting, a grassroots group of former CDC employees who were terminated this year, told Axios the organization holds rallies each Tuesday in support of people who still work at the agency. "It's really hard to put into words how horrible this experience has been, not just for us, but it's going to really affect everybody in America," she said. Eric Mintz, another former CDC employee, told Axios proposed cuts to the CDC, National Institutes for Health, Food and Drug Administration and Medicaid will take away resources needed to protect people from illnesses. "It's not waste, it's not abuse, it's not fraud," Mintz said. "It's hard-working people with expertise trying to protect the American citizens." Catch up quick: The Health and Human Services Department in March announced about 2,400 positions would be eliminated from the CDC. HHS has said reducing its workforce from 82,000 to 62,000 full-time employees will cut costs from the agency's nearly $2 trillion budget. On Monday, RFK. Jr. removed all 17 members from the expert panel that makes vaccine policy recommendations to the CDC. He said in a statement the agency is "prioritizing the restoration of public trust above any specific pro- or anti-vaccine agenda." Questions are still being raised on who runs the CDC, as there is no public health official or designated point person leading the agency. State of play: Trump's fiscal year 2026 budget also recommends cutting $3.59 billion from the CDC. The budget, which was approved by the U.S. House, is still lingering in the U.S. Senate. Threat level: Anna Yousaf, an infectious diseases doctor at the CDC's National Center for Immunization and Respiratory Diseases, called Kennedy a "domestic health threat" who has dismantled programs ranging from lead poisoning prevention to maternal and infant health monitoring.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store